Drug Database
SC

Scherersol delivery systems (Polysol / Quadrisol / Cosol)

✓ Approved

Cardinal Health, Inc. · Small Molecule · Small Molecule

What is Scherersol delivery systems?

Scherersol delivery systems is a small molecule developed by Cardinal Health, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesPolysol, Quadrisol, Cosol
CompanyCardinal Health, Inc.
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Cardinal Health, Inc.

Therapeutic Indications

Scherersol delivery systems is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026-08-25

Intranasal essential oils in therapy: advances in clinical applications and delivery mechanisms.

Yong Liang L, Qiuyan Guan G, Yi Chen C, Wei W U WU et al.

This review comprehensively examines the therapeutic mechanisms, formulation advancements, and clinical applications of intranasal essential oil (EO) delivery, aiming to highlight its potential as a modern therapeutic approach. A systematic literature search was conducted in PubMed and Web of Science up to May 2024, focusing on preclinical and clinical studies. Data on target diseases, delivery mechanisms, formulation innovations, and therapeutic effects were extracted and analyzed. Intranasal EO delivery demonstrates significant therapeutic potential for neurological, respiratory, cardiovascular, and metabolic disorders. Advanced delivery systems, including nanoemulsions, liposomes, and nasal in situ gels, enhance EO stability, bioavailability, and targeted release. Mechanistically, EOs exert effects through neurotransmission modulation, anti-inflammatory pathways, and vascular regulation, primarily via the olfactory and trigeminal nerves. Clinical evidence supports the efficacy of intranasal EOs in conditions such as anxiety, depression, allergic rhinitis, and hypertension, although further optimization is needed to minimize irritation and improve patient adherence. Intranasal delivery of EOs offers a promising strategy for enhancing therapeutic administration and expanding clinical applications. Future research should focus on developing advanced in vivo pharmacokinetic evaluation tools, optimizing delivery systems, ensuring safety, and integrating EOs with conventional therapies to support their broader clinical translation.

PMID 42639787
Read full article →
PubMedFrontiers in pharmacology2026-08-25

Local drug delivery systems for the periodontal microenvironment: from barrier penetration to multilevel synergy.

An Huilin H, Lin Qinxiao Q, Zhai Mengru M, Zhou Pengcen P et al.

Periodontitis is a chronic inflammatory disease characterized by progressive destruction of periodontal supporting tissues. Although local drug delivery systems (LDDSs) enable site-specific therapy, their clinical efficacy remains limited by the dynamic and heterogeneous periodontal microenvironment. This review systematically delineates multiscale barriers to effective delivery, including biofilm resistance, gingival crevicular fluid (GCF)-mediated clearance, immune-mediated degradation, and impaired tissue regeneration. In response, LDDS design has evolved from passive carriers to multilevel synergistic systems, integrating responsiveness to multiple stimuli and programmed release that aligns with the antibacterial-anti-inflammatory-regenerative sequence. The emergence of theranostic platforms further enables real-time monitoring and feedback-controlled intervention. Despite these advances, a significant translational gap persists. Current models fail to recapitulate the polymicrobial and chronic nature of periodontitis, while overlooked in vivo phenomena, including protein corona formation and the reactive oxygen species (ROS) paradox, may compromise therapeutic outcomes. Future strategies should prioritize physiological relevance and precise spatiotemporal regulation to facilitate clinical translation of LDDSs.

PMID 42639423
Read full article →
PubMedSheng wu gong cheng xue bao = Chinese journal of biotechnology2026-08-25

[Responsive DNA origami for mRNA delivery].

Zhao Ji J, Wang Jiaming J, Song Jie J, Zhan Pengfei P

mRNA technology has emerged as a crucial tool in fields including vaccinology, gene therapy, and regenerative medicine. However, mRNA is susceptible to rapid degradation by ribonucleases (RNases) in physiological environments, and its large molecular weight and negative charge hinder its transmembrane delivery into cells. Existing delivery systems face key bottlenecks such as insufficient serum stability, limited cellular uptake efficiency, and a lack of controlled intracellular release mechanisms. Consequently, there is an urgent need to develop novel delivery platforms that offer both robust protective capabilities and precisely controlled release. In this study, a barrel-shaped DNA nanostructure was constructed using DNA origami technology, and its structural integrity was verified using agarose gel electrophoresis, atomic force microscopy (AFM), and transmission electron microscopy (TEM). The stability of the mRNA-origami complex was further assessed under 10% fetal bovine serum (FBS) conditions, and its cellular uptake behavior was evaluated in HT29 cells. Building on this platform, a stimulus-responsive release strategy was further developed by incorporating an ultraviolet-activatable PC linker, enabling photo-controlled release and thereby achieving responsive mRNA translation expression. The constructed photo-controlled release system allows programmable intracellular dissociation and release upon specific stimuli. By combining carrier structure optimization with a stimulus-responsive mechanism, a comprehensive intelligent mRNA delivery strategy was established. This study provides novel design concepts and experimental paradigms for constructing nucleic acid delivery systems with high stability, efficient cellular uptake, and controllable release capability.

PMID 42638062
Read full article →
PubMedAdvanced healthcare materials2026-08-25

From Cell-Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery.

Baldari Clara C, Leone Claudia C, Leccese Gabriella G, De Stradis Claudia C et al.

Nonviral gene therapy reached unprecedented clinical prominence, with the approval of lipid nanoparticles (LNPs). Yet, their success remains largely confined to a narrow range of applications and tissues, which reflects the inherent functional constraints based on formulation optimization to overcome intrinsically complex physiological barriers. In contrast, biological membranes evolved to integrate immune evasion, targeting, intracellular trafficking, and membrane fusion within a single functional interface. In this review, we provide a mechanistic comparison between membrane-derived vesicles (MDVs) and hybrid biomimetic systems. We critically examine MDVs from different biological sources, highlighting their unique advantages for gene delivery applications. We also focus on hybrid systems, which merge the biological functionality of naturally derived membranes with the design control of synthetic nanovectors to address key limitations such as inefficient cytosolic release, poor targeting specificity, and transfection of hard-to-engineer cells. This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane-integrated nanovesicles (NVs) as "living interfaces" for non-viral gene therapy.

PMID 42639936
Read full article →
PubMedBiomaterials science2026-08-25

Regulating the membrane-fusion effect of liposomes via the protonation of tertiary amines.

Lin Xiaobing X, Tang Le L, Zheng Huijuan H, Wang Ke K et al.

Membrane fusion, a fundamental biological process enabling precise exchange of biomolecules within and between cells, has inspired the development of various fusogenic model systems for applications in drug delivery and beyond. However, conventional systems typically operate in an "always-on" state, lacking spatiotemporal control. Although cleavable polyethylene glycol coatings can confer temporal regulation through stimuli-responsive activation, such strategies are often unidirectional and synthetically challenging. Here, we report a simple yet reversible strategy to regulate liposomal membrane fusion via protonation of tertiary amines. By replacing the permanently positively charged lipid DOTAP with an ionizable analogue, DODAP, we constructed a pH-switchable fusogenic liposome (PsFul) that remains inactive at neutral pH but activates fusion upon protonation in acidic environments. This transition is fully reversible, allowing adaptive toggling between "on" and "off" states. We demonstrate that PsFul enables direct cytosolic delivery of anticancer drugs via membrane fusion, bypassing lysosomal entrapment and significantly enhancing cytotoxicity under acidic conditions. This work establishes a facile platform for achieving spatially and temporally controlled membrane fusion, offering promising potential for targeted therapeutic delivery.

PMID 42639698
Read full article →
PubMedRSC advances2026-08-25

Nb2C-based MXenes for controlled cyclophosphamide delivery: role of surface functionalization and sulfur doping.

Govindan Madhumitha M, Petchimuthu Rooban R, Baskaran Anitha A, Sivasankar Kumar Janani J et al.

A systematic first-principles study was performed to explore the pristine Nb2C, Nb2CO2, and S-doped Nb2CO2 MXenes as potential nanocarriers for cyclophosphamide (CYP) drug delivery in breast cancer therapy. Density functional theory calculations were employed to examine the structural stability, electronic properties, adsorption behaviour and solvation effects of all systems. Cohesive energy calculations and ab initio molecular dynamics simulations confirmed the structural and thermal stability of all nanocarriers at 298 K. Electronic structure analysis revealed that the metallic nature of the MXenes is preserved after functionalization, sulfur doping and drug adsorption. Adsorption studies showed that pristine Nb2C exhibits strong interaction with CYP, with an adsorption energy of -1.02 eV, indicating chemisorption. In contrast, Nb2CO2 displayed relatively weak physisorption. Sulfur doping effectively modulates the adsorption strength, and the 4S-doped Nb2CO2 configuration exhibited -0.85 eV of adsorption energy with reduced charge transfer, suggesting a favourable balance between drug loading and release. Implicit solvation calculations showed that both isolated and drug-loaded systems are stable under aqueous conditions, with solvation energies of up to -0.36 and -0.74 eV, respectively. Recovery time analysis at physiological temperature (310 K) further confirms the suitability of these MXenes for drug release. Among all investigated nanocarriers, 4S-doped Nb2CO2 MXene is emerging as a candidate for CYP drug delivery applications.

PMID 42639352
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Scherersol delivery systems